256 related articles for article (PubMed ID: 16701982)
21. Changing trends in the epidemiology of Candida blood stream infections: a matter for concern?
Sobel JD
Crit Care Med; 2010 Mar; 38(3):990-2. PubMed ID: 20168159
[No Abstract] [Full Text] [Related]
22. In vitro antifungal susceptibility of clinical isolates of Candida spp. obtained from patients with different predisposing factors to candidosis.
Pinto PM; Weikert-Oliveira Rde C; Lyon JP; Cury VF; Arantes RR; Koga-Ito CY; Resende MA
Microbiol Res; 2008; 163(5):579-85. PubMed ID: 16962755
[TBL] [Abstract][Full Text] [Related]
23. Voriconazole: a broad spectrum triazole for the treatment of serious and invasive fungal infections.
Maschmeyer G; Haas A
Future Microbiol; 2006 Dec; 1(4):365-85. PubMed ID: 17661629
[TBL] [Abstract][Full Text] [Related]
24. Treatment of invasive infections due to rare or emerging yeasts and moulds.
Sahin GO; Akova M
Expert Opin Pharmacother; 2006 Jun; 7(9):1181-90. PubMed ID: 16732704
[TBL] [Abstract][Full Text] [Related]
25. Increasing fungal infections in the intensive care unit.
De Pauw BE
Surg Infect (Larchmt); 2006; 7 Suppl 2():S93-6. PubMed ID: 16895517
[TBL] [Abstract][Full Text] [Related]
26. The changing epidemiology of invasive fungal infections: new threats.
Maschmeyer G
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():3-6. PubMed ID: 16707250
[TBL] [Abstract][Full Text] [Related]
27. Optimizing therapy for Candida infections.
Playford EG; Sorrell TC
Semin Respir Crit Care Med; 2007 Dec; 28(6):678-88. PubMed ID: 18095232
[TBL] [Abstract][Full Text] [Related]
28. Candida glabrata fungaemia in a tertiary centre in Taiwan: antifungal susceptibility and outcomes.
Ruan SY; Huang YT; Chu CC; Yu CJ; Hsueh PR
Int J Antimicrob Agents; 2009 Sep; 34(3):236-9. PubMed ID: 19361960
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of antifungals in the surgical intensive care unit: a multi-institutional study.
Garey KW; Neuhauser MM; Bearden DT; Cannon JP; Lewis RE; Gentry LO; Kontoyiannis DP
Mycoses; 2006 May; 49(3):226-31. PubMed ID: 16681815
[TBL] [Abstract][Full Text] [Related]
30. Impact of real-time fungal susceptibility on clinical practices.
Magiorakos AP; Hadley S
Curr Opin Infect Dis; 2004 Dec; 17(6):511-5. PubMed ID: 15640704
[TBL] [Abstract][Full Text] [Related]
31. Antifungal susceptibility testing of micafungin against Candida glabrata isolates.
Oliveira ER; Fothergill A; Kirkpatrick WR; Patterson TF; Redding SW
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Apr; 105(4):457-9. PubMed ID: 18329581
[TBL] [Abstract][Full Text] [Related]
32. Update on antifungal resistance in Aspergillus and Candida.
Arendrup MC
Clin Microbiol Infect; 2014 Jun; 20 Suppl 6():42-8. PubMed ID: 24372701
[TBL] [Abstract][Full Text] [Related]
33. Fluconazole-resistant pseudomembranous oral candidiasis.
Shetty K
Ann Pharmacother; 2006 May; 40(5):993. PubMed ID: 16638917
[No Abstract] [Full Text] [Related]
34. Therapeutic efficacy of voriconazole against a fluconazole-resistant Candida albicans isolate in a vaginal model.
González GM; Portillo OJ; Uscanga GI; Andrade SE; Robledo M; Rodríguez C; Elizondo M
J Antimicrob Chemother; 2009 Sep; 64(3):571-3. PubMed ID: 19570754
[TBL] [Abstract][Full Text] [Related]
35. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.
Horn DL; Neofytos D; Anaissie EJ; Fishman JA; Steinbach WJ; Olyaei AJ; Marr KA; Pfaller MA; Chang CH; Webster KM
Clin Infect Dis; 2009 Jun; 48(12):1695-703. PubMed ID: 19441981
[TBL] [Abstract][Full Text] [Related]
36. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest.
Fleck R; Dietz A; Hof H
J Antimicrob Chemother; 2007 Apr; 59(4):767-71. PubMed ID: 17293369
[TBL] [Abstract][Full Text] [Related]
37. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy.
Hachem R; Hanna H; Kontoyiannis D; Jiang Y; Raad I
Cancer; 2008 Jun; 112(11):2493-9. PubMed ID: 18412153
[TBL] [Abstract][Full Text] [Related]
38. Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program.
Pfaller MA; Diekema DJ; Colombo AL; Kibbler C; Ng KP; Gibbs DL; Newell VA
J Clin Microbiol; 2006 Oct; 44(10):3578-82. PubMed ID: 17021085
[TBL] [Abstract][Full Text] [Related]
39. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.
Pfaller MA; Diekema DJ; Gibbs DL; Newell VA; Meis JF; Gould IM; Fu W; Colombo AL; Rodriguez-Noriega E;
J Clin Microbiol; 2007 Jun; 45(6):1735-45. PubMed ID: 17442797
[TBL] [Abstract][Full Text] [Related]
40. Antifungal resistance in Candida spp. isolated in Italy between 2002 and 2005 from children and adults.
Gualco L; Debbia EA; Bandettini R; Pescetto L; Cavallero A; Ossi MC; Schito AM; Marchese A
Int J Antimicrob Agents; 2007 Feb; 29(2):179-84. PubMed ID: 17175140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
